Trethera Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 3

Trethera General Information

Description

Developer of nucleotide metabolism drugs designed to provide treatment of cancer and autoimmune diseases. The company's drugs are deoxycytidine kinase inhibitor that improves bioavailability and demonstrates anti-tumor activity in combination therapies, enabling patients to avail of drugs that improve treatment efficacy and overcome the limitations of single-agent therapies.

Contact Information

Website
www.trethera.com
Formerly Known As
Triangle Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 13547 Ventura Boulevard
  • Suite 363
  • Sherman Oaks, CA 91423
  • United States
+1 (310)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Vertical(s)
TMT, Life Sciences, Oncology
Corporate Office
  • 13547 Ventura Boulevard
  • Suite 363
  • Sherman Oaks, CA 91423
  • United States
+1 (310)

Trethera Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Trethera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Accelerator/Incubator 26-Oct-2023 Completed Generating Revenue
7. Grant 30-May-2023 Completed Generating Revenue
6. Grant 19-Oct-2022 Completed Clinical Trials - Phase 1
5. Later Stage VC 17-May-2022 Completed Clinical Trials - Phase 1
4. Later Stage VC 23-Feb-2021 Completed Clinical Trials - Phase 1
3. Later Stage VC 17-Apr-2019 Completed Clinical Trials - Phase 1
2. Seed Round 03-Mar-2017 $19.1M $19.1M Completed Clinical Trials - Phase 1
1. University Spin-Out 12-Sep-2015 Completed Startup
To view Trethera’s complete valuation and funding history, request access »

Trethera Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed 3
Seed 2
Seed 670,000 $0.001000 $1.2 $15 $15 1x $15 5.1%
To view Trethera’s complete cap table history, request access »

Trethera Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Trethera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11446307-B2 Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof Active 02-Nov-2020
US-20220135555-A1 Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof Active 02-Nov-2020
US-20220133735-A1 Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof Inactive 02-Nov-2020
AU-2021368138-A1 Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof Pending 02-Nov-2020
EP-4237421-A1 Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof Pending 02-Nov-2020 C07D417/12
To view Trethera’s complete patent history, request access »

Trethera Executive Team (11)

Name Title Board Seat
Kenneth Schultz MD Chief Executive Officer, President, Board Member & Chairman
Jean DeKernion MD President & Board Member
David Nathanson Ph.D Co-Founder
Caius Radu MD Scientific Co-Founder
Carl McKinzie Secretary & Board Member
You’re viewing 5 of 11 executive team members. Get the full list »

Trethera Board Members (7)

Name Representing Role Since
Carl McKinzie Trethera Secretary & Board Member
Jean DeKernion MD Trethera President & Board Member
Kenneth Schultz MD Trethera Chief Executive Officer, President, Board Member & Chairman
Laurent Dubois Self Board Member
Louis Gonda Self Board Member
You’re viewing 5 of 7 board members. Get the full list »

Trethera Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trethera Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
LifeSciences@Work Accelerator/Incubator
National Cancer Institute Government
National Eye Institute Government
To view Trethera’s complete investors history, request access »

Ready to get started?

Request a free trial

Trethera FAQs

  • When was Trethera founded?

    Trethera was founded in 2013.

  • Who is the founder of Trethera?

    David Nathanson Ph.D, Caius Radu MD, Michael Jung Ph.D, Owen Witte MD, and Johannes Czernin MD are the founders of Trethera.

  • Who is the CEO of Trethera?

    Kenneth Schultz MD is the CEO of Trethera.

  • Where is Trethera headquartered?

    Trethera is headquartered in Sherman Oaks, CA.

  • What is the size of Trethera?

    Trethera has 6 total employees.

  • What industry is Trethera in?

    Trethera’s primary industry is Drug Discovery.

  • Is Trethera a private or public company?

    Trethera is a Private company.

  • What is Trethera’s current revenue?

    The current revenue for Trethera is .

  • How much funding has Trethera raised over time?

    Trethera has raised $34.8M.

  • Who are Trethera’s investors?

    LifeSciences@Work, National Cancer Institute, and National Eye Institute have invested in Trethera.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »